JG
Therapeutic Areas
Sana Biotechnology Pipeline
| Drug | Indication | Phase |
|---|---|---|
| UP421 | Type 1 Diabetes | Pre-Clinical |
| SC451 | Type 1 Diabetes | Pre-Clinical |
| SG293 (CD8/CD19) | B-cell Malignancies; Autoimmune Diseases | Pre-Clinical |
Leadership Team at Sana Biotechnology
SH
Steve Harr
President and Chief Executive Officer
AG
Aaron Grossman
Executive Vice President, Chief Legal Officer
GM
Gary Meininger
Chief Medical Officer
DP
Dhavalkumar Patel
Chief Scientific Officer
SP
Snehal Patel
Chief Technical Officer
BP
Brian Piper
Executive Vice President, Chief Financial Officer
YS
Yuko Soneoka
Head of Intellectual Property
DW
Debra Wisdom
Vice President, Head of People
SW
Susan Wyrick
Finance and Accounting
HB
Hans Bishop
Chairman of the Board